Sequencing to Synthesis: Precision Antibody Discovery Leveraging Machine Learning to Prioritize Leads
Current industry practice for antibody (Ab) generation and validation can take months, involving extensive wet lab labor and resource usage. Even after an elaborate Ab campaign, the candidates often still have developability issues that can result in late-stage failure. This inefficient process is laborious and costly, thus there is a need for new ways to discover Ab lead candidates with precision and efficiency.
The GENEWIZ precision antibody discovery (PAD) workflow increases the success of antibody screening as compared to traditional methods by:
- Uncovering 5-10x more antibody leads
- Increasing library diversity with 5-50x more clusters, including rare clones
- Focusing research efforts on the most commercially successful leads through reduced sequence liabilities
Download the poster now to see the data!